if you're dealing with pharma techs or stocks, when the fda decides whether or not to approve a given treatment, these are data points that could send a stock soaring higher when they go your way. you need to know there's a moment to buy before the catalyst and a moment most importantly that seem to get wrong, too, after the catalyst happen. sometimes the event won't work or maybe the data point you're speccing turns out to be less. when you buy a stock as a trade, it has a limited shelf life. once the window passes, you must sell, sell, sell. if you rack up nice gains, there's no point in sticking around. ring the register. but if it turns out to be wrong -- >> the house of pain. >> you still need to -- >> sell, sell, sell. >> when you buy a bottle of milk, you don't drink it after the expiration date. you throw it away. and you never, ever should own anything without a reason. people fool themselves into doing the right thing. more often than not, they get crushed. without a catalyst, you don't have a trade. if you find yourself in that position, you had better sell and cut your low

we've seen other pharma giants gobbling up oncology-centered techs. to name a new, amgen and astrazeneca. >> morgan, thank you very much. to dominic chu for a quick "market flash." >> check out what's happening with amgen, the biotech is coming off its lows that its experimental cholesterol drug succeeded in a late-stage drug. it prevents the liver from removing bad cholesterol. those shares are starting to come off those lows. back to you. >> thank you very much. implgts three big stories today about the safety of the american consumer. big credit card breach, perhaps you've heard about it, at target. a news report on the safest cars on the road. that's another one. and this is a scary one. nearly half the chickens in america infected by a superbug that is immune to antibiotics. we'll get to that one in just a moment. first, mary thompson, jane wells, phil lebeau covering all three. mary, you first. >> we've been talking about this all morning, tyler. it is the biggest data breach at a u.s. retailer since 2005 when data for 90 million tjx customers w

. >> it was mentioned in the previous statement, the tech sector, that is up 30% from industrials, pharma about, up 30%, this is a broad base rally and anything about the valuation is trailing or futureing, we are in the midteens, not necessarily expensive, back in the 90s more than that. in 2007 it was more than that and your bond portfolio in the balance allocation was way overvalued, at 14% and they have--and only three and you tell me someone will go out and choose blondes instead of stocks, i don't think so. would argue a lot of things are expensive. we are and global asset bubble. bonds are expensive, stocks are expensive, commodities expensive, they got beaten up but we wonder why with all the money printing going on across the world's top gold, silver, and they should all be doing really well. to his point, in 2007-99 things were more expensive but today things cannot be considered cheap by any metric. corporate profits as a percentage of gdp are as high as they have ever been. last year was a wonderful year. this is not sustainable. not even close. cheryl: what is your concern. y

tech was extraordinary. you know? gilliad. one of the great horses of this era. it's a very big company now. a very, very big company versus major pharma in mind of herbalife. shares of which are up able i believe 111%. >> it was near the end of the quarter and year and bill stears and it was the auditor itself with a problem. >> right. >> not -- you know, similar -- you know, there's magnet hunter i like with the same thing. >> investors are focused on when the audit is official and made because there is still this belief that they'll then undertake a large recapitalization. >> remember, 80% of the sales from overseas and the idea to have a government company try to shut -- i'm sorry. government entity try to bring down herbalife is dimmer and dimmer and dimmer. >> you pointed out -- that's a 13d by the way. he's an active investor in herbalife and put 400 plus million dollars of his own money into it. >> i was with a food executive recently saying that con-ag struggled with the acquisition of bill stears. people forget, carl, this is a guy i revered because the food group used to have all this, you know, all these different buy and s